Area of exposure and treatment challenges of malaria in Eritrean migrants: a GeoSentinel analysis

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Patricia Schlagenhauf, WHO Collaborating Centre for Travel Medicine, Travel Clinic and Department of Public Health, Epidemiology, Biostatistics and Prevention Institute, University of Zürich, 8001, Zurich, Switzerland. Patricia.schlagenhauf@uzh.ch.
  • ,
  • Martin P Grobusch, Centre for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
  • ,
  • Davidson H Hamer, Department of Global Health, Boston University School of Public Health and Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
  • ,
  • Hilmir Asgeirsson, Unit of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • ,
  • Mogens Jensenius, Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.
  • ,
  • Gilles Eperon, Division of Tropical and Humanitarian Medicine, Department of Community Medicine, Primary and Emergency Care, Geneva University Hospitals (HUG), Geneva, Switzerland.
  • ,
  • Camilla Rothe, Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Munich, Germany.
  • ,
  • Egon Isenring, WHO Collaborating Centre for Travel Medicine, Travel Clinic and Department of Public Health, Epidemiology, Biostatistics and Prevention Institute, University of Zürich, 8001, Zurich, Switzerland.
  • ,
  • Jan Fehr, University Hospital, Department of Infectious Diseases, University of Zürich, Zurich, Switzerland.
  • ,
  • Eli Schwartz, The Center of Geographical Medicine-Dept. of Internal Medicine "C"-Sheba Medical Center Tel HaShomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • ,
  • Emmanuel Bottieau, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  • ,
  • Elizabeth D Barnett, Maxwell Finland Laboratory for Infectious Diseases, Boston Medical Center, Boston, MA, USA.
  • ,
  • Anne McCarthy, Children's Hospital of Eastern Ontario (CHEO) Research Institute; Department of Pediatrics and School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, ON, Canada.
  • ,
  • Paul Kelly, Bronx Lebanon Hospital, New York, USA.
  • ,
  • Carsten Schade Larsen
  • Perry van Genderen, Institute for Tropical Diseases, Harbour Hospital Rotterdam, Rotterdam, The Netherlands.
  • ,
  • William Stauffer, Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, USA.
  • ,
  • Michael Libman, J.D. MacLean Centre for Tropical Diseases, McGill University, Montreal, Canada.
  • ,
  • Philippe Gautret, University Hospital Institute for Infectious and Tropical Diseases, Aix-Marseille University, Marseille, France.

BACKGROUND: Recent reports highlight malaria as a frequent diagnosis in migrants who originate from Eritrea. A descriptive analysis of GeoSentinel cases of malaria in Eritrean migrants was done together with a literature review to elucidate key attributes of malaria in this group with a focus on possible areas of acquisition of malaria and treatment challenges.

RESULTS: A total of 146 cases were identified from the GeoSentinel database from 1999 through September 2017, with a marked increase in 2014 and 2015. All patients originated from Eritrea and the main reporting GeoSentinel sites were in Norway, Switzerland, Sweden, Israel and Germany. The majority of patients (young adult males) were diagnosed with malaria following arrival in the host country. All patients had a possible exposure in Eritrea, but may have been exposed in documented transit countries including Ethiopia, Sudan and possibly Libya in detention centres. Most infections were due to Plasmodium vivax (84.2%), followed by Plasmodium falciparum (8.2%). Two patients were pregnant, and both had P. vivax malaria. Some 31% of the migrants reported having had malaria while in transit. The median time to onset of malaria symptoms post arrival in the host country was 39 days. Some 66% of patients were hospitalized and nine patients had severe malaria (according to WHO criteria), including five due to P. vivax.

CONCLUSIONS: The 146 cases of mainly late onset, sometimes severe, P. vivax malaria in Eritrean migrants described in this multi-site, global analysis reflect the findings of single-centre analyses identified in the literature search. Host countries receiving asylum-seekers from Eritrea need to be prepared for large surges in vivax and, to a lesser extent, falciparum malaria, and need to be aware and prepared for glucose-6-phosphate dehydrogenase deficiency testing and primaquine treatment, which is difficult to procure and mainly unlicensed in Europe. There is an urgent need to explore the molecular epidemiology of P. vivax in Eritrean asylum-seekers, to investigate the area of acquisition of P. vivax along common transit routes and to determine whether there has been re-introduction of malaria in areas, such as Libya, where malaria is considered eliminated, but where capable vectors and Plasmodium co-circulate.

OriginalsprogEngelsk
TidsskriftMalaria Journal
Vol/bind17
Nummer1
Sider (fra-til)443
ISSN1475-2875
DOI
StatusUdgivet - 29 nov. 2018

Se relationer på Aarhus Universitet Citationsformater

ID: 137844549